Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;13(7):1833-1839.
doi: 10.1007/s40123-024-00965-4. Epub 2024 May 18.

Sustained Release Therapies with the Prostaglandin Analogues Intracameral Implants

Abdelrahman M Elhusseiny  1   2 , Ahmad A Aref  3
Affiliations

Sustained Release Therapies with the Prostaglandin Analogues Intracameral Implants

Abdelrahman M Elhusseiny et al. Ophthalmol Ther. 2024 Jul.

Abstract

The travoprost intracameral implant was recently approved by the US Food and Drug Administration for sustained release medical treatment of open-angle glaucoma in the USA. The approval represents a substantial and progressive step forward in the area of sustained-release glaucoma therapy. Topical intraocular pressure-lowering medications for the treatment of glaucoma are faced with a host of challenges for long-term and usually lifelong care. A changing paradigm in glaucoma management involves first-line interventions with laser modalities, micro-invasive surgeries, and sustained-release treatment platforms. Future needs in the area of sustained-release therapy include a non-prostaglandin drug delivery platform and longer-term treatments that do not require surgical reintervention.

Keywords: Drug delivery; Glaucoma; IOP; Implant; Intraocular; Sustained release; Travoprost.

PubMed Disclaimer

Conflict of interest statement

Ahmed A. Aref consults for Alcon, New World Medical, Nova Eye Medical, and Dompe. Ahmed A. Aref receives research funding from Abbvie and travel support from Oculus Surgical. Ahmed A. Aref is an Advisory Board member of Ophthalmology and Therapy. Ahmed A. Aref was not involved in the selection of peer reviewers for the manuscript nor any subsequent editorial decisions. Abdelrahman M. Elhusseiny has nothing to disclose.

Figures

Fig. 1
Fig. 1
Design of the travoprost intracameral implant (iDose® TR). Printed with permission from Glaukos Corporation
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016;2:16067. doi: 10.1038/nrdp.2016.67. - DOI - PubMed
    1. Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis Sci. 2014;55(1):102–109. doi: 10.1167/iovs.13-13006. - DOI - PubMed
    1. Wesselink C, Stoutenbeek R, Jansonius NM. Incorporating life expectancy in glaucoma care. Eye (Lond) 2011;25(12):1575–1580. doi: 10.1038/eye.2011.213. - DOI - PMC - PubMed
    1. Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern®. Ophthalmology. 2021;128(1):P71–p150. doi: 10.1016/j.ophtha.2020.10.022. - DOI - PubMed
    1. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961. doi: 10.1016/j.ophtha.2004.12.035. - DOI - PubMed

LinkOut - more resources